LFMD logo

LIFEMD INC

LFMDNASDAQ
πŸ† #3922 by market capEarnings Nov 16US Equity
$104.73β–² $7.30 (+6.97%)
Simulated price
πŸ””
Track LFMD
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.0%
7dβ–² 3333.8%
14dβ–² 3162.6%
30dβ–² 3300.3%
ytdβ–² 2962.3%
1yβ–² 1440.1%
🏦Market Cap
$139M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-16.7%
Declining
πŸ“ŠGross Margin
69.4%
High
πŸ’΅FCF Margin
3.8%
Moderate
βš–οΈP/S Ratio
0.7x
Cheap
Otter Score
40
Weak

Trading Snapshot

Day Range
$103.06 – $106.45
52-Week Range
$2.56 – $7.32
Volume
$1.77B
Avg Volume
$1.91B
Shares Outstanding
48.4M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$194M
Last Q Revenue
$47M
P/E Ratio
690.6
P/S Ratio
0.7x
EPS (TTM)
$0.01
Dividend Yield
2.24%
Dilution (1yr)
+10.8%

Why Investors Own LFMD

  • βœ“High-growth profile β€” revenue up -4.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 68% gross margin and 7% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LFMD logo

LIFEMD INC

LFMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$194Mβ–Ό βˆ’8.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.8%β–Ό βˆ’10.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–Ό βˆ’52.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$1Mβ–Ό βˆ’120.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.8Mβ–² +10.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$30Mβ–² +$21M YoY
StockOtter Β· stockotter.space

About LIFEMD INC

LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
40/100

Analyst Price Target

β“˜
Average Target
$113.56
β–² +8.4% Upside
High Target$137.02
Low Target$102.70
Based on 26 analysts

Latest News & Updates